NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, reported its financial and ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular ...

So should NervGen Pharma ( CVE:NGEN) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company ...

Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for ...

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Cipher Pharmaceuticals (CPHRF – Research Report) today and set a price ...

The 80's and 90's spawned a host of selling models and most of us in the pharma business have been trained to use one or multiple different selling models. However, how many pharma executives ...

The Indian pharma sector is flexing its muscles. In the last 12 months, the NSE Pharma has returned 50%, comfortably beating the Nifty that went up by 31%, while also returning an average 19% over ...

Nifty 50 CEOs and MDs earning over ₹50 crore, doubled in 2023-24 from 2018-19 One in five CEOs and MDs earned more than ₹50 crore in the the last fiscal year, compared with one in 10, five ...